Molecular characterization of PRM associated endometrial changes, PAEC, following mifepristone treatment The progesterone receptor modulator (PRM) Mifepristone hold the potential to be developed for regular contraception. However, long-term treatment can cause thickening of the endometrium and PRM associated endometrial changes (PAEC). The objective of this study was to explore the molecular expression of endometrium displaying PAEC after mifepristone treatment, in order to understand the future implications of PAEC and safety of long-term use.
Morbid obesity: potential effects of hormonal contraception Obesity has wide-ranging health consequences. It is strongly associated with cardiovascular risk factors such as diabetes, hypertension and dyslipidemia. In addition, obese patients have an increased risk of coronary artery disease, stroke and venous thromboembolism (VTE). These diseases result in obesity being an issue with important global implications for cardiovascular dysfunction. Furthermore, obesity may have an adverse effect on virtually all systems in the body, and it is the fifth leading cause of mortality worldwide .
Contraceptive information on pregnancy resource center websites: a statewide content analysis Most pregnancy resource centers (PRCs) in the US are affiliated with national organizations that have policies against promoting or providing contraceptives, yet many provide information about contraception on their websites. In 2016, the state of Georgia passed a new law to publicly fund PRCs. This study sought to describe the contraceptive information on Georgia PRC websites.
The intrauterine device as emergency contraception: how much do young women know? Unprotected intercourse is common, especially among teens and young women. Access to intrauterine device (IUD) as emergency contraception (EC) can help interested patients more effectively prevent unintended pregnancy and can also offer ongoing contraception. This study evaluated young women's awareness of IUD as EC and interest in case of need.
Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer Understanding the effect of contraceptives on the development of precancerous lesions of the cervix and cervical cancer may provide information that is valuable to women in contraceptive decision-making. The purpose of this study was to evaluate the association between recent intrauterine device (IUD) use (by type) and cervical intraepithelial neoplasia 2, 3, adenocarcinoma in situ or cancer (CIN2+ or CIN3+).
Ensuring our research reflects our values: The role of family planning research in advancing reproductive autonomy Debates about women’s reproductive health and reproductive health care often reflect fundamental disagreements about women’s autonomy and agency over their bodies. As reflected in Dr. George Tiller’s guiding philosophy, whether or not politicians, policy makers, and advocates “trust women” is a central division in discussions around abortion restrictions and contraceptive provision. For those committed to advancing women’s empowerment, the belief in women’s reproductive autonomy — defined as their ability and fundamental right to make and act on decisions about their bodies, including whether to have sex, whether to use contraception to prevent pregnancy, and whether to continue a pregnancy  — is a fundamental ethical foundation.
Medicaid and fulfillment of desired postpartum sterilization We sought to assess fulfillment of sterilization requests while accounting for the complex interplay between insurance, clinical and social factors in a contemporary context that included both inpatient and outpatient postpartum sterilization procedures.
Use of Copper Intrauterine Device in Transgender Male Adolescents Transgender men need contraception if engaging in intercourse with a cis-gender male partner. The copper IUD is an effective, non-hormonal contraceptive well suited for trans-males even while utilizing gender affirming hormone therapy. A gender-neutral medical facility with well-trained and sensitive staff is the ideal setting to provide such contraceptive care.
Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception? Heavy menstrual bleeding (HMB), which affects as many as 30% of women, has a well- established negative impact on quality of life and work productivity [1,2]. In women with chronic HMB in the absence of known anatomic abnormalities (fibroids, adenomyosis), options such as non-steroidal anti-inflammatory drugs (NSAIDs) , combined hormonal contraceptives , the levonorgestrel intrauterine system , danazol  and tranexamic acid  show varying degrees of efficacy for reduction of menstrual flow and are often able to restore normal day-to-day function.
A systematic review of contraceptive continuation among women living with HIV Women living with HIV (WLHIV) experience high rates of unmet contraceptive need and unintended pregnancy. Contraceptive method-specific continuation rates and associated factors are critical for guiding providers tasked with both reproductive health (RH) and HIV care. We conducted this systematic review to determine whether contraceptive continuation rates differ between WLHIV and uninfected women and, for WLHIV, whether differences are impacted by method type, antiretroviral therapy use or other factors.
Society of Family Planning clinical guidelines pain control in surgical abortion part 1 — local anesthesia and minimal sedation Satisfactory pain control for women undergoing surgical abortion is important for patient comfort and satisfaction. Clinicians ought to be aware of the safety and efficacy of different pain control regimens. This document will focus on nonpharmacologic modalities to reduce pain and pharmacologic interventions up to the level of minimal sedation. For surgical abortion without intravenous medications, a multimodal approach to pain control may combine a dedicated emotional-support person, visual or auditory distraction, administration of local anesthesia to the cervix with buffered lidocaine and a preoperative nonsteroidal anti-inflammatory drug.
Family planning providers' role in offering PrEP to women Pre-exposure prophylaxis (PrEP) provides a radically different HIV prevention option for women. Not only is PrEP the first discrete, woman-controlled method that is taken in advance of exposure, but it is both safe and highly effective, offering over 90% protection if taken daily. While multiple modalities of PrEP are in development ranging from vaginal rings to injectables and implants, only PrEP with oral tenofovir/emtricitabine is currently FDA-approved. Family planning clinics provide key access points for many women to learn about and obtain PrEP.
Aviso para pacientes:
Esta página contiene información urológica dirigida a profesionales de la sanidad.
Si tiene algún problema relacionado con esta patología,
consulte con su urólogo o médico de familia.
Si desea información diseñada para pacientes y público general. puede visitar:
Portal de Información Urológica para Pacientes